Brief: Neurotech International Granted U.S. FDA Pre-Ind Meeting For Nti164 In Autism Spectrum Disorder
19/01/2023 24:42
Jan 19 (Reuters) - Neurotech International Ltd NTI.AX :
* GRANTED U.S. FDA PRE-IND MEETING FOR NTI164 IN AUTISM
SPECTRUM
DISORDER
Source text for Eikon: ID:nASXccFRZy
Further company coverage: NTI.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neurotech International
See all newsBrief: Neurotech International Says Anthony Filippis Resigns As CEO, MD
Brief: Neurotech International Appoints Mark Davies As Executive Chairman
Brief: Neurotech International Receives Binding Commitments For Around A$4.50 Million In Placement At A$0.014 Per Share
Australia's Neurotech International slips to a month low on discounted placement
Brief: Neurotech International Requests Trading Halt